Presentation of the result of Medivir’s voluntary redemption programme

Stockholm, Sweden – Medivir AB (Nasdaq Stockholm: MVIR) today announces the result of Medivir’s voluntary redemption programme. The redemption programme comprised a total of 6,738,655 shares in Medivir. Upon completion of the application period, a total of 6,647,060 shares have been registered for redemption, whereof 131,589 series A shares and 6,515,471 series B shares, corresponding to an acceptance level of 98.6 per cent. In total, cash proceeds of approximately SEK 857.5 million will be distributed to the shareholders, corresponding to SEK 129 per redeemed share, to be paid around 24 March 2017.

Following completion of the redemption programme, the total number of outstanding shares in Medivir will amount to 20,318,977 shares, whereof 474,769 series A shares and 19,844,208 series B shares, and the total number of votes will amount to 24,591,898 votes.

Commission-free sale
For the commission-free sale of redemption rights, the average sales proceeds amounted to SEK 13.26 per redemption right. Payment of proceeds of the commission-free sale of redemption rights is expected to be made to the relevant shareholders around 3 March 2017.

Trading in redemption shares
Trading in redemption shares is expected to commence on 8 March 2017 and end on 15 March 2017.

For further information, please contact:
Ola Burmark, CFO Medivir AB, mobile: +46 (0)725-480 580.

The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 3 March 2017.

About Medivir
Medivir develops innovative pharmaceutical products for the treatment of cancer. The company specialises in protease inhibitor research and nucleotide/nucleoside science and conducts research in all stages of the drug development process, from original idea to clinical phase III studies. Its development work is done both in-house and through partnerships.

Tags:

About Us

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Collaborations and partnerships are important parts of Medivir's business model and the drug development as well as the commercialization is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

Subscribe

Documents & Links